(BANB) Bachem Holding - Ratings and Ratios

Bachem Holding AG is a leading global provider of peptide and oligonucleotide active pharmaceutical ingredients to the pharmaceutical and biotechnology industries. The companys comprehensive portfolio encompasses development, production, and regulatory support for new chemical entities, commercial products, and generics. By offering a range of services, including project management, quality and regulatory support, analytical services, and GMP production, Bachem enables its clients to outsource critical aspects of their operations, leveraging the companys expertise and capabilities to accelerate their product development and commercialization.

With a history dating back to 1971 and headquartered in Bubendorf, Switzerland, Bachem has established itself as a trusted partner in the pharmaceutical industry, with a strong track record of delivering high-quality products and services. The companys website (https://www.bachem.com) provides further information on its capabilities, products, and services.

Analyzing the available data, we can observe that Bachems stock has experienced significant fluctuations over the past year, with a 52-week high of 89.00 CHF and a low of 44.03 CHF. Currently, the stock is trading at 53.95 CHF, with its SMA20 and SMA50 indicating a potential uptrend. However, the SMA200 suggests that the stock is still below its long-term trend. Considering the ATR of 1.38 CHF (2.56%), the stocks volatility is relatively moderate.

From a fundamental perspective, Bachems market capitalization stands at 4045.06M CHF, with a P/E ratio of 33.72 and a forward P/E of 32.68, indicating a relatively high valuation. Nevertheless, the companys return on equity (RoE) of 16.10% suggests a strong ability to generate profits for its shareholders.

Based on the available technical and fundamental data, a forecast for Bachem Holding AG can be constructed. Considering the current price of 53.95 CHF, the SMA20 and SMA50 trends, and the relatively high P/E ratio, a potential price target could be around 60-65 CHF in the short to medium term, representing a 11-20% increase. However, this forecast is contingent upon the companys ability to maintain its RoE and continue delivering strong financial performance. If the company can achieve this, the stock may be poised for a rebound, potentially reaching its SMA200 level or even surpassing it.